ProjectUpdated on 4 September 2025
Novel MET Amplification-Targeting Small-Molecule Kinase Inhibitor (HJ-462 BIC)
About
HJ-462 features protein kinase inhibitors with ingenious molecular designs that avoid defects in drug metabolism within the body, resulting in excellent safety and remarkable efficacy(achieving 100% tumor regression in liver cancer, gastric cancer, and lung cancer models caused by MET amplification, effectively curing these conditions).
Project Location
- China
Project Format
- Private Project
ESG (Environmental, Social, and Governance)
- Yes
Project Stage
- Feasibility Study Completed
Main Project Sector
- Technology
Technology
- Bio-Tech
Interested Format of Cooperation
- Joint Venture
- Minority Shareholdings
- Open for Negotiation
- R&D Cooperation
Preferred Financing Model
- Equity
- Open for negotiation
Previous Funding Stage
- Seed & Pre-Series
Main Service(s) Required
- Financial Services
- Professional Services
Financial Services
- Institutional Investment
- Private Equity & Venture Capital
Professional Services
- Business Valuation
- Corporate Services
- Market Entry Strategic Analysis
Attached files
Organisation
Shanghai Haiju Biotechnology Co., Ltd.
Shanghai, China
Similar opportunities
Project
Novel Platinum-Based Drug Targeting Tumor Microenvironment (HJ-550 )
- Yes
- Equity
- Bio-Tech
- Technology
- Joint Venture
- Legal Advisory
- Private Project
- R&D Cooperation
- Seed & Pre-Series
- Financial Services
- Investment Banking
- Business Valuation
- Corporate Services
- Open for Negotiation
- Professional Services
- Minority Shareholdings
- Feasibility Study Completed
- Private Equity & Venture Capital
Haiyang Wang
CEO at Shanghai Haiju Biotechnology Co., Ltd.
Shanghai, China
Project
- No
- Bio-Tech
- Operations
- Technology
- IP Related
- Consultancy
- R&D Cooperation
- Risk Management
- Health Technology
- Seed & Pre-Series
- Medical Technology
- Financial Services
- Business Valuation
- Financial Advisory
- Open for Negotiation
- Open for negotiation
- Professional Services
- 5,000,001 to 7,500,000 USD
- 10,000,001 to 25,000,000 USD
- Private Equity & Venture Capital
- Public-Private Partnership Project
- Risk Management (Financial Services)
Jiang Liu
Research Assistant Professor at Oncoimmunostics Limited
Hong Kong, China (Hong Kong)
Project
Single Cell Drug Screening AI Platform
- Yes
- None
- Equity
- Bio-Tech
- Technology
- Private Project
- R&D Cooperation
- Open for negotiation
- Professional Services
- Minority Shareholdings
- 2,500,001 to 5,000,000 USD
- 1,000,001 to 2,500,000 USD
- Feasibility Study Completed
- Public–private partnership / Concession
Marco Suen
Founder & CEO at Provectus Therapeutics Limited
Hong Kong, China (Hong Kong)